Evaluation of the Association of Transferrin Receptor Type 2 Gene Mutation (Y250X) with Iron Overload in Major β-Thalassemia

Document Type : Short Communication

Authors

Department of Biology, College of Science, Al Muthanna University, Samawah, Iraq

Abstract

Thalassemia is an inherited blood disorder in which the body produces defective hemoglobin. One of the important processes to reduce the complication of major β-thalassemia is blood transfusion that leads to elevated ferritin levels in the blood. Many patients who have major β-thalassemia may have hemochromatosis conditions resulting from iron metabolism disorders. In patients who have β-thalassemia, the mutation Y250X in the TFR2 gene may play a role in the incidence of hemochromatosis. This study aimed to determine the relationship between ferritin levels and Y250X mutation in major β-thalassemia patients. In the present study, 12 blood samples were divided into nine major β-thalassemia patients and three healthy controls. The DNA was isolated from blood samples and the amplification of the target region was performed based on the specific primers. Sanger sequencing was used to find genetic single nucleotide polymorphisms associated with iron overload. Blood parameters, such as hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, and serum ferritin levels were analyzed and the recorded data showed the following results: 8.1±0.8 g/dL, 84.6±5.5 fL, 27±0.7 pg, respectively. The recorded data showed that the mean serum ferritin level in major β-thalassemia patients was 1921.7±848 ng/mL. The Y250X mutation was not found in major β-thalassemia patients and healthy controls.

Keywords

References

  1. Gao J, Chen J, De Domenico I, Koeller DM, Harding CO, Fleming RE, et al. Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice. Blood. 2010;115(16):3374-81.
  2. Camaschella C, Roetto A, Calì A, De Gobbi M, Garozzo G, Carella M, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000;25(1):14-5.
  3. del-Castillo-Rueda A, Moreno-Carralero M-I, Cuadrado-Grande N, Álvarez-Sala-Walther L-A, Enríquez-de-Salamanca R, Méndez M, et al. Mutations in the HFE, TFR2, and SLC40A1 genes in patients with hemochromatosis. Gene. 2012;508(1):15-20.
  4. Ding K, Shameer K, Jouni H, Masys DR, Jarvik GP, Kho AN, et al., editors. Genetic Loci implicated in erythroid differentiation and cell cycle regulation are associated with red blood cell traits. Mayo Clinic Proceedings; 2012.
  5. Silvestri L, Nai A, Pagani A, Camaschella C. The extrahepatic role of TFR2 in iron homeostasis. Front Pharmacol. 2014;5:93.
  6. Zarghamian P, Azarkeivan A, Arabkhazaeli A, Mardani A, Shahabi M. Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy. BMC Med Gen. 2020;21(1):75.
  7. Drake SF, Morgan EH, Herbison CE, Delima R, Graham RM, Chua AC, et al. Iron absorption and hepatic iron uptake are increased in a transferrin receptor 2 (Y245X) mutant mouse model of hemochromatosis type 3. Am J Physiol Gastrointest. Liver Physiol. 2007;292(1):G323-G8.
  8. Piperno A, Pelucchi S, Mariani R. Inherited iron overload disorders. Transl Gastroenterol Hepatol. 2020;5:25.
  1. Schmidt PJ, Fitzgerald K, Butler JS, Fleming MD. Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model. Am J Hematol. 2021;96(2):251-7.
  2. Cappellini MD. Exjade®(deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag. 2007;3(2):291.
  3. Sun S-Y, Guo Y-H, Sun Z-M, Wu Y-H, Li M-X. Analysis of HFE and Non-HFE mutations in a Tibet cohort with iron overload. Zhongguo shi yan xue ye xue za zhi. 2019;27(2):618-22.
  4. Santos P, Cancado R, Terada C, Rostelato S, Gonzales I, Hirata R, et al. HFE gene mutations and iron status of Brazilian blood donors. Braz J Med Biol. 2010;43:107-14.
  5. Aguilar-Martinez P, Esculié-Coste C, Bismuth M, Giansily-Blaizot M, Larrey D, Schved J-F. Transferrin receptor-2 gene and non-C282Y homozygous patients with hemochromatosis. Blood Cells Mol Dis. 2001;27(1):290-3.
  6. Kawabata H, Fleming RE, Gui D, Moon SY, Saitoh T, O'Kelly J, et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood. 2005;105(1):376-81.
  7. Fleming RE, Ahmann JR, Migas MC, Waheed A, Koeffler HP, Kawabata H, et al. Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. PNAS. 2002;99(16):10653-8.

16.          Piperno A, Roetto A, Mariani R, Pelucchi S, Corengia C, Daraio F, et al. Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica. 2004;89(3):359-60.

Archives of Razi Institute
Volume 76, Issue 5
November and December 2021
Pages 1551-1554

Files

Share

How to cite

Statistics